Canada mandated that cereal grains, especially white flour, be fortified with folic acid by mid-1998. Between 0.1 and 0.2 mg of additional synthetic folic acid per day has been provided through this initiative. The current paper describes how this took place, and the epidemiological effects that occurred in the Canadian population, including higher blood folate levels and a decline in the prevalence of neural tube defects.
LumleyJWatsonLWatsonMBowerC. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst, 2001: Rev CD001056.
2.
RayJGSinghGBurrowsRF. Evidence for suboptimal use of periconceptional folic acid supplements globally. BJOG2004;111:399–408.
3.
Folic acid fortification. US Food and Drug Administration, Office of Public Affairs Fact Sheet. February 29, 1996. Available at: http://www.cfsan.fda.gov/∼dms/wh-folic.html. Accessed 20 March 2008.
Hannon-FletcherMPArmstrongNCScottJMPentievaKBradburyIWardMStrainJJDunnAAMolloyAMKerrMAMcNultyH. Determining bioavailability of food folates in a controlled intervention study. Am J Clin Nutr2004;80:911–8.
6.
CuskellyGJMcNultyHScottJM. Effect of increasing dietary folate on red-cell folate: Implications for prevention of neural tube defects. Lancet1996;347:657–9.
7.
Per capita consumption of major food groups (other). CANSIM, table 002–0019. StatisticsCanada: Ottawa. Available at: http://www40.statcan.ca/l01/cst01/famil102e.htm. Accessed 20 March 2008.
8.
Evaluation of food fortification with folic acid for the primary prevention of neural tube defects. Executive summary 1997–2003. Ottawa: Public Health Agency of Canada, 2005. Available at: http://www.phac-aspc.gc.ca/publicat/faaf/pdf/folic_acid_e.pdf. Accessed 21 March 2008.
9.
RayJGVermeulenMJBossSCColeDE. Increased red cell folate concentrations in women of reproductive age after Canadian folic acid food fortification. Epidemiology2002;13:238–40.
10.
RayJGVermeulenMJLangmanLJBossSCColeDE. Persistence of vitamin B12 insufficiency among elderly women after folic acid food fortification. Clin Biochem2003;36:387–91.
11.
PersadVLVan den HofMCDubeJMZimmerP. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ2002;167:241–5.
12.
RayJGMeierCVermeulenMJBossSWyattPRColeDE. Association of neural tube defects and folic acid food fortification in Canada. Lancet2002;360:2047–8.
13.
De WalsPRusenIDLeeNSMorinPNiyonsengaT. Trend in prevalence of neural tube defects in Quebec. Birth Defects Res A Clin Mol Teratol2003;67:919–23.
14.
BoydPAArmstrongBDolkHBottingBPattendenSAbramskyLRankinJVrijheidMWellesleyD. Congenital anomaly surveillance in England—ascertainment deficiencies in the national system. BMJ2005;330:27.
15.
RayJGVermeulenMJMeierCColeDEWyattPR. Maternal ethnicity and risk of neural tube defects: A population-based study. CMAJ2004;171:343–5.
16.
RayJGMeierCVermeulenMJWyattPRColeDE. Association between folic acid food fortification and congenital orofacial clefts. J Pediatr2003;143:805–7.
17.
RayJGMeierCVermeulenMJColeDEWyattPR. Prevalence of trisomy 21 following folic acid food fortification. Am J Med Genet2003;120A:309–13.
18.
RayJGMamdaniMM. Association between folic acid food fortification and hypertension or preeclampsia in pregnancy. Arch Intern Med2002;162:1776–7.
19.
McDonaldSDVermeulenMJRayJG. Folic acid and placental pathology. Epidemiology2005;16:419–20.
20.
DickinsonCJ. Does folic acid harm people with vitamin B12 deficiency?QJM1995;88:357–64.
21.
DharMBellevueRCarmelR. Pernicious anemia with neuropsychiatric dysfunction in a patient with sickle cell anemia treated with folate supplementation. N Engl J Med2003;348:2204–7.
22.
CarmelR. Subtle and atypical cobalamin deficiency states. Am J Hematol1990;34:108–14.
23.
WhittleSLHughesRA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: A review. Rheumatology (Oxford)2004;43:267–71.
24.
RayJGLangmanLJMamdaniMMColeDE. Absence of effect of folic acid flour fortification on anticonvulsant drug levels. Am J Med2005;118:444–5.
25.
SchiffM. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clin Ther2003;25:993–1001.
